Firebrick Pharma Limited (ASX:FRE) Filings

Firebrick Pharma Limited

Filings

FilingDateTypeFiled with
Notification regarding unquoted securities - FRENov 16, 2026Other filingsASX
Change of Director's Interest Notice - Stephen GoodallNov 16, 2026Ownership change noticeASX
Change of Director's Interest Notice - Rick LegleiterNov 16, 2026Ownership change noticeASX
Change of Director's Interest Notice - Peter MolloyNov 16, 2026Ownership change noticeASX
Change of Director's Interest Notice - Al MoghaddamNov 16, 2026Ownership change noticeASX
Proposed issue of securities - FRENov 11, 2026FinancingASX
Results of Annual General MeetingNov 10, 2026Meeting outcomeASX
September 2026 Quarterly Activity Report & Appendix 4COct 22, 2026Quarterly reportASX
New Product - Nasodine Sinus RinseOct 20, 2026Operations updateASX
New Product - Nasodine Sinus RinseOct 20, 2026Operations updateASX
Change in substantial holding - Pharma NutriaOct 19, 2026Ownership change noticeASX
Cleansing NoticeOct 18, 2026FinancingASX
Application for quotation of securities - FREOct 18, 2026FinancingASX
Nasodine Nasal Spray Approved in the PhilippinesOct 15, 2026Operations updateASX
Notice of AGM & Proxy Form & Letter to ShareholdersOct 11, 2026Meeting noticeASX
Proposed issue of securities - FREOct 11, 2026FinancingASX
Firebrick Secures $732k in Strategic InvestmentsOct 11, 2026FinancingASX
Firebrick Investor Update PresentationOct 6, 2026Operations updateASX
Firebrick announces USA Retail Launch PlanSep 28, 2026Operations updateASX
Firebrick receives $293,000 R&D Tax IncentiveSep 22, 2026ResultsASX
Notice of AGM and Closing Date for Director NominationsSep 14, 2026Meeting noticeASX
Appendix 4E and Annual Report 30 June 2026Aug 31, 2026Annual reportASX
Appendix 4GAug 31, 2026Other filingsASX
Corporate Governance StatementAug 31, 2026Other filingsASX
Cleansing NoticeAug 10, 2026Notification letterASX
Application for quotation of securities - FREAug 10, 2026FinancingASX
Proposed issue of securities - FREAug 9, 2026FinancingASX
Investor UpdateJul 26, 2026Operations updateASX
March 2026 Quarterly Activity Report & Appendix 4CApr 21, 2026Quarterly reportASX
Firebrick Secures $1.5 million via PlacementMar 30, 2026FinancingASX
Trading HaltMar 26, 2026Trading halt or suspensionASX
Registration Agreement and Approval of Nasodine in IndonesiaMar 26, 2026Operations updateASX
Appendix 4D & Half-Year Financial Report to 31 December 2025Feb 24, 2026Interim reportASX
December 2025 Quarterly Activity Report & Appendix 4CJan 27, 2026Quarterly reportASX
Nasodine Throat Spray Product Launch in SingaporeJan 20, 2026Operations updateASX
Firebrick announces new product Nasodine Throat SprayOct 29, 2025Operations updateASX
September 2025 Quarterly Activity Report & Appendix 4COct 22, 2025Quarterly reportASX
Firebrick Secures Investment from Philippines PartnerOct 15, 2025FinancingASX
Firebrick receives $250,000 R&D Tax IncentiveSep 9, 2025FinancingASX
Appendix 4E and Annual Report 30 June 2025Aug 29, 2025Annual reportASX
Firebrick Secures $1.4 million via PlacementAug 25, 2025FinancingASX
License Agreement for Singapore, Malaysia, Brunei, MauritiusAug 25, 2025Material contractASX
June 2025 Quarterly Activity Report & Appendix 4CJul 22, 2025Quarterly reportASX
Firebrick Closes Placement at $0.2 milliionJun 25, 2025FinancingASX
Withdrawal of Share PlacementJun 6, 2025FinancingASX
March 2025 Quarterly Activity Report & Appendix 4CApr 16, 2025Quarterly reportASX
FRE secures Strategic Investment from Philippines PartnerMar 3, 2025Other filingsASX
Appendix 4D & Half-Year Financial Report to 31 December 2024Feb 20, 2025Interim reportASX
December 2024 Quarterly Activity Report & Appendix 4CJan 22, 2025Quarterly reportASX
Nasodine Retail Pharmacy Launch in SingaporeNov 24, 2024Other filingsASX
Agreement Signed to Market Nasodine to HCPs in SingaporeOct 30, 2024Other filingsASX
September 2024 Quarterly Activity Report & Appendix 4COct 22, 2024Quarterly reportASX
Completion of Share Purchase PlanOct 9, 2024FinancingASX
Firebrick receives $0.9 million R&D Tax IncentiveSep 22, 2024Other filingsASX
Share Purchase PlanSep 11, 2024FinancingASX
Appendix 4E and Annual Report 30 June 2024Aug 30, 2024Annual reportASX
New agreement allows Nasodine launch in PhilippinesAug 14, 2024Operations updateASX
June 2024 Quarterly Activity Report & Appendix 4CJul 29, 2024Quarterly reportASX
Firebrick Launches Nasodine in SingaporeJun 12, 2024Operations updateASX
Firebrick Raises $800,000 via PlacementMay 16, 2024FinancingASX
March 2024 Quarterly Activity Report & Appendix 4CApr 22, 2024Quarterly reportASX
Nasodine Nasal Spray Launch in the USAApr 16, 2024Operations updateASX
Appendix 4D & Half-Year Financial Report to 31 December 2023Feb 28, 2024Interim reportASX
December 2023 Quarterly Activity Report & Appendix 4CJan 23, 2024Quarterly reportASX
Firebrick Investor UpdateNov 14, 2023Operations updateASX
Firebrick Receives $1.81m R&D Tax IncentiveOct 30, 2023FinancingASX
September 2023 Quarterly Activity Report & Appendix 4COct 26, 2023Quarterly reportASX
Update on Nasodine Trial and Forward PlansOct 2, 2023Operations updateASX
Phase 3 Common Cold Trial ResultsSep 13, 2023Other filingsASX
Appendix 4E & Annual Report FY23Aug 29, 2023Annual reportASX
Response to ASX Price and Volume QueryAug 28, 2023Explanation requestASX
Firebrick Phase 3 Trial Closes with 500 SubjectsAug 8, 2023Other filingsASX
Firebrick Covid-19 Trial Achieves Primary EndpointAug 6, 2023Other filingsASX
June 2023 Quarterly Activity Report & Appendix 4CJul 26, 2023Quarterly reportASX
Nasodine Phase 3 Clinical Trial Surpasses 80% RecruitmentMay 30, 2023Other filingsASX
Firebrick Raises $1 million via PlacementApr 30, 2023FinancingASX
March 2023 Quarterly Activity Report & Appendix 4CApr 19, 2023Quarterly reportASX
Nasodine COVID-19 Trial Concludes RecruitmentApr 3, 2023Other filingsASX
Firebrick Pharmas Phase 3 Trial of Nasodine ResumesMar 20, 2023Other filingsASX
FRE files EU Paediatric Investigation Plan for NasodineFeb 20, 2023Legal or regulatory actionASX
Appendix 4D & Half Yearly Report and AccountsFeb 17, 2023Interim reportASX
December 2022 Quarterly Activity Report & Appendix 4CJan 18, 2023Quarterly reportASX
Nasodine Composition Patent Accepted in AustraliaNov 13, 2022Other filingsASX
Firebrick Receives $1.08m R&D Tax IncentiveNov 8, 2022Other filingsASX
September 2022 Quarterly Activity Report & Appendix 4COct 31, 2022Quarterly reportASX
Appendix 4E & Annual ReportAug 23, 2022Annual reportASX
June 2022 Quarterly Activity Report & Appendix 4CJul 28, 2022Quarterly reportASX
Outcome of s60 appeal for Nasodine and next stepsJul 7, 2022Other filingsASX
Firebrick starts Phase 3 common cold trial of NasodineMay 3, 2022Other filingsASX
March 2022 Quarterly Activity Report & Appendix 4CApr 26, 2022Quarterly reportASX
Firebrick starts COVID-19 trial of NasodineApr 26, 2022Other filingsASX
31 December Interim Financial Report & Appendix 4DFeb 11, 2022Interim reportASX